Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mismatch Repair

Mismatch Repair

Mismatch Repair

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

Next-generation Sequencing

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....

In vitro Mutagenesis

In vitro Mutagenesis

Sanger Sequencing

Sanger Sequencing

DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Benzo[b]fluoranthene Induces Mutation Accumulation and Cancer-Relevant Mutational Signatures in Mouse Lung Alongside Steady State Levels of Chromosome Damage in Blood.

Environmental and molecular mutagenesis·2026

Same author

Ontogeny of Placental FcRn Protein During Human and Animal Pregnancy to Inform Developmental Toxicity Testing.

Birth defects research·2026

Same author

Report From the International Conference on Incontinentia Pigmenti: Translating Discovery to Therapy.

American journal of medical genetics. Part A·2026

Same author

Human iPSC-derived macrophages for studying intrinsic and extrinsic factors in cystic fibrosis.

EXO : beyond the cell·2026

Same author

Understanding the provider experience with digital tools in blended care therapy delivered via telehealth: A mixed-methods evaluation.

Digital health·2026

Same author

Minimizing use of nonhuman primates to inform risk to fertility and of adverse pregnancy outcomes with pharmaceuticals.

Regulatory toxicology and pharmacology : RTP·2026

Same journal

Resveratrol Mitigates Haloacetaldehyde Disinfection By-Products (HAL-DBPs)-Induced Oocyte Developmental Toxicity via Mitochondria-Dependent Pathways.

Environmental and molecular mutagenesis·2026

Same journal

DZNep: A Methyltransferase Modulator for Disease Mitigation.

Environmental and molecular mutagenesis·2026

Same journal

Transcriptional Dysregulation of Histone Methyltransferase Genes and Chromosomal Instability Associated With Chronic Pesticide Exposure.

Environmental and molecular mutagenesis·2026

Same journal

Evaluation of Type 1 Error Rates in Duplex Sequencing for Mutagenicity Testing Using Vehicle Control Data and Simulation Analyses.

Environmental and molecular mutagenesis·2026

Same journal

Multi-Omics Integration Into Adverse Outcome Pathway Framework: Principles, Progress, and Prospects for Next-Generation Toxicological Risk Assessment.

Environmental and molecular mutagenesis·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 28, 2026

Rare Event Detection Using Error-corrected DNA and RNA Sequencing

Rare Event Detection Using Error-corrected DNA and RNA Sequencing

Published on: August 3, 2018

Benchmark Response Values for Error-Corrected Sequencing Mutagenicity Assessment Technologies.

Saron Mulugeta^1,2, Francesco Marchetti^2,3, Guangchao Chen⁴

¹School of Computer Science, Carleton University, Ottawa, Ontario, Canada.

Environmental and Molecular Mutagenesis

|April 27, 2026

Summary

This summary is machine-generated.

Establishing a consistent Benchmark Response (BMR) for error-corrected sequencing (ECS) mutagenicity testing is crucial for accurate risk assessment. This study proposes a 30% BMR for in vivo ECS technologies, enhancing dose-response modeling and human health evaluations.

Keywords:

HAWK‐seq PECC‐seq PROAST PacBio HiFi benchmark dose duplex sequencing effect size risk assessment

More Related Videos

Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter

Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter

Published on: March 31, 2022

Genome-wide Surveillance of Transcription Errors in Eukaryotic Organisms

Genome-wide Surveillance of Transcription Errors in Eukaryotic Organisms

Published on: September 13, 2018

Related Experiment Videos

Last Updated: Apr 28, 2026

Rare Event Detection Using Error-corrected DNA and RNA Sequencing

Rare Event Detection Using Error-corrected DNA and RNA Sequencing

Published on: August 3, 2018

Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter

Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter

Published on: March 31, 2022

Genome-wide Surveillance of Transcription Errors in Eukaryotic Organisms

Genome-wide Surveillance of Transcription Errors in Eukaryotic Organisms

Published on: September 13, 2018

Area of Science:

Toxicology and Risk Assessment
Genetics and Genomics
Molecular Biology

Background:

The Benchmark Dose (BMD) approach is vital for risk assessment, but selecting a Benchmark Response (BMR) for continuous endpoints remains challenging.
Error-corrected sequencing (ECS) technologies offer advanced mutagenicity assessment, necessitating standardized BMR values for reliable interpretation.
Previous work established a 50% BMR for specific in vivo mutagenicity assays, highlighting the need for technology-specific BMRs.

Purpose of the Study:

To compare two methods for defining BMR values for ECS technologies: Effect Size (ES) theory and the one standard deviation approach.
To determine technology-specific within-group variance values for BMR calculations using a compiled ECS dose-response database.
To propose a standardized BMR for in vivo ECS mutagenicity assessment to improve consistency in risk evaluation.

Main Methods:

Compiled a dose-response database from various in vivo error-corrected sequencing studies.
Applied the Effect Size (ES) theory and the one standard deviation approach to define BMR values.
Examined experimental factors influencing within-group variance (var) to justify using technology-specific var values for BMR determination.

Main Results:

No significant influence of experimental factors (species, strain, route, time, tissue, DNA method) on within-group variance was detected.
Calculated technology-specific BMRs: 27.7% for Duplex Sequencing (DupSeq), 16.6% for Hawk-Seq, and 23.3% for PECC-Seq.
BMRs derived from negative control values ranged from 5.6% to 31.5% across different ECS technologies.

Conclusions:

The study supports the adoption of a 30% BMR for in vivo error-corrected sequencing mutagenicity assessment technologies.
A standardized BMR provides a robust and consistent foundation for future dose-response modeling in toxicology.
This approach will enhance the reliability of human health risk assessments based on advanced mutagenicity testing.